London’s Al Saqi Books Closes Its Doors End of December

London’s Al Saqi Books Closes Its Doors End of December
TT

London’s Al Saqi Books Closes Its Doors End of December

London’s Al Saqi Books Closes Its Doors End of December

Sad news! London’s Al Saqi Books, which served as a cultural center for 44 years, announced closing its doors on December 31.

The general situation, long lockdowns, and the increasing costs of papers and shipping have aggravated the crisis of libraries, publishers, and everything related to books. Like many victims affected in these fragile professions, especially those working in the field of Arabic books, this esteemed library, which played a central role for Arabs and non-Arabs interested in Arabic books in the UK, has decided to put an end to its journey.

“The various lockdowns and the ensuing breakdown of supply chains negatively impacted many independent businesses, such as ours. But as a specialist Arab-world bookseller sourcing our stock from the Middle East and North Africa, we also had to contend with sharp increases in Arabic-language book prices, shipping charges and exchange rates,” owner Salwa Gaspard told the Bookseller Magazine.

“For me, Al Saqi is more than just a library. I grew up in Al Saqi, my sister and I spent hours playing around books. I was honored to work in it with my parents. We will miss the library but we are looking forward to the next chapter in Al Saqi history from our new location in western London. We are thrilled to bring the best new and classic books from the Arab world to the United Kingdom and other countries within the coming years,” saddened Lyn Gaspard said about the library that her parents co-founded with Mai Ghoussoub.

Al Saqi Books, London, was established in 1979 by friends Mai Ghoussoub and Andre Gaspard, it was the first Arabic library in the UK. In 1982, they opened a special section in the library for English books about the Middle East, and then launched English publishing in 1983. Al Saqi started Arabic publishing in 1987 supported by its strong ties with its readers and other London-based publishers.
Dar Al Saqi publishing was founded in Beirut, in 1991, pledging to promote intellectual innovation and the renaissance of Arabic culture.

It acted as a bridge between the Arabic and western cultures by encouraging dialogue, introducing the western culture to the Arab readers, and showcasing causes that concern the Arabic society in the west.

The Arabic publishing house, which also established “Al Saqi Kids and Youth” in 2012, won many prizes. After its closure in London, Al Saqi is still alive and struggling for survival in Beirut.

“Although Al Saqi is closing its doors in London, its heritage will continue with its two independent publishing houses: Dar Al Saqi for Arabic Publishing (Beirut), and Saqi Books for English publishing in London,” Dar Al Saqi said in a statement.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”